{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:03:19Z","timestamp":1788436999649,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Universidade Feevale","award":["25.173.16.2500"],"award-info":[{"award-number":["25.173.16.2500"]}]},{"name":"Incentivo \u00e0 Pesquisa e Eventos from Hospital de Cl\u00ednicas de Porto Alegre","award":["13-0341"],"award-info":[{"award-number":["13-0341"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.clinbiochem.2018.04.001","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T11:03:18Z","timestamp":1522839798000},"page":"18-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicity"],"prefix":"10.1016","volume":"56","author":[{"given":"Olavo Vicente","family":"Neto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suziane","family":"Raymundo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Alice","family":"Franzoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andiara","family":"do Carmo Artmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariane","family":"Tegner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria Vendramini","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Zilles","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Vasconcelos","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Schwartsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Venzon","family":"Antunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2018.04.001_bb0005","series-title":"Principios de Farmacologia. 2a. Rio de Janeiro","first-page":"627","article-title":"Farmacologia do C\u00e2ncer: S\u00edntese, Estabilidade e Manuten\u00e7\u00e3o do Genoma","author":"Barbie","year":"2012"},{"key":"10.1016\/j.clinbiochem.2018.04.001_bb0010","series-title":"As Bases Farmacol\u00f3gicas da Terap\u00eautica de Goodmam e Gilmam","first-page":"1678","article-title":"Agentes Citot\u00f3xicos","volume":"Vol. 12a","author":"Brunton","year":"2012"},{"issue":"6","key":"10.1016\/j.clinbiochem.2018.04.001_bb0015","first-page":"549","article-title":"Dihydropyrimidine dehydrogenase and fluoropyrimidines: a review of current dose adaptation practices and the impact on the future of personalized medicine using 5-fluorouracil","volume":"2","author":"Boisdron-Celle","year":"2013","journal-title":"Color. Cancer"},{"issue":"4","key":"10.1016\/j.clinbiochem.2018.04.001_bb0020","first-page":"219","article-title":"Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in folfox chemotherapy for metastatic colorectal cancer","volume":"13","author":"Goldstein","year":"2014","journal-title":"Clin. Colorectal Cancer"},{"issue":"4","key":"10.1016\/j.clinbiochem.2018.04.001_bb0025","first-page":"381","article-title":"Prospective, multicenter study of 5-fluorouracil therapeutic drug monitoring in metastatic colorectal Cancer treated in routine clinical practice","volume":"15","author":"Wilhelm","year":"2016","journal-title":"Clin. Colorectal Cancer"},{"issue":"3","key":"10.1016\/j.clinbiochem.2018.04.001_bb0030","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/bcp.13007","article-title":"Pronounced between-subject and circadian variability in thymidylate synthase and dihydropyrimidine dehydrogenase enzyme activity in human volunteers","volume":"82","author":"Jacobs","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"22","key":"10.1016\/j.clinbiochem.2018.04.001_bb0035","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/jnci\/djp328","article-title":"Pharmacokinetically Guided Dose Adjustment of 5-Fluorouracil: A Rational Approach to Improving Therapeutic Outcomes","volume":"101","author":"Saif","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.clinbiochem.2018.04.001_bb0040","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.surg.2009.05.005","article-title":"Circadian variation in intestinal dihydropyrimidine dehydrogenase (DPD) expression: a potential mechanism for benefits of 5FU chrono-chemotherapy","volume":"146","author":"Abolmaali","year":"2009","journal-title":"Surgery"},{"issue":"2","key":"10.1016\/j.clinbiochem.2018.04.001_bb0045","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1634\/theoncologist.2015-0322","article-title":"Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications","volume":"21","author":"Buil-Bruna","year":"2016","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.clinbiochem.2018.04.001_bb0050","doi-asserted-by":"crossref","first-page":"271","DOI":"10.32635\/2176-9745.RBC.2013v59n2.535","article-title":"Individualiza\u00e7\u00e3o Farmacocin\u00e9tica das Doses de 5-Fluoruracil no C\u00e2ncer Colorretal","volume":"59","author":"Martins","year":"2013","journal-title":"Rev. Bras. Cancerol."},{"issue":"9","key":"10.1016\/j.clinbiochem.2018.04.001_bb0055","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1634\/theoncologist.2014-0132","article-title":"A community-based multicenter trial of Pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal Cancer therapy","volume":"19","author":"Patel","year":"2014","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.clinbiochem.2018.04.001_bb0060","first-page":"1","article-title":"Impact of DPYD variants in fluoropyrimidine based-therapy: the state of the art","volume":"1","author":"Catapano","year":"2014","journal-title":"World Cancer Res. J."},{"issue":"2","key":"10.1016\/j.clinbiochem.2018.04.001_bb0065","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ejca.2006.09.017","article-title":"Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin","volume":"43","author":"van Kuilenburg","year":"2007","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.clinbiochem.2018.04.001_bb0070","first-page":"224","article-title":"Routine Dihydropyrimidine Dehydrogenase Testing for Anticipating 5-Fluorouracil\u2013Related Severe Toxicities: Hype or Hope?","volume":"9","author":"Ciccolini","year":"2010","journal-title":"Clin. Colorectal Cancer"},{"issue":"11","key":"10.1016\/j.clinbiochem.2018.04.001_bb0075","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1158\/1535-7163.MCT-06-0327","article-title":"Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance","volume":"5","author":"Morel","year":"2006","journal-title":"Mol. Cancer Ther."},{"issue":"49","key":"10.1016\/j.clinbiochem.2018.04.001_bb0080","doi-asserted-by":"crossref","first-page":"81880","DOI":"10.18632\/oncotarget.11980","article-title":"Determining the optimal 5-FU therapeutic dosage in the treatment of colorectal cancer patients","volume":"7","author":"Fang","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.clinbiochem.2018.04.001_bb0085","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ejca.2003.12.004","article-title":"Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil","volume":"40","author":"van Kuilenburg","year":"2004","journal-title":"Eur. J. Cancer"},{"issue":"13","key":"10.1016\/j.clinbiochem.2018.04.001_bb0090","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","article-title":"Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal Cancer","volume":"26","author":"Gamelin","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2018.04.001_bb0095","first-page":"119","article-title":"Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal Cancer patients treated with Infusional 5\u2013fluorouracil-based chemotherapy regimens","volume":"13","author":"Kline","year":"2014","journal-title":"Clin. Colorectal Cancer"},{"issue":"4","key":"10.1016\/j.clinbiochem.2018.04.001_bb0100","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00280-014-2553-2","article-title":"Pretherapeutic uracil and dihydrouracil levels in saliva of colorectal cancer patients are associated with toxicity during adjuvant 5-fluorouracil-based chemotherapy","volume":"74","author":"Carlsson","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"16\u201317","key":"10.1016\/j.clinbiochem.2018.04.001_bb0105","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.clinbiochem.2016.07.004","article-title":"Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies","volume":"49","author":"Galarza","year":"2016","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.clinbiochem.2018.04.001_bb0110","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.trac.2016.07.010","article-title":"Saliva as an alternative specimen to plasma for drug bioanalysis. A review","volume":"83","author":"Elmongy","year":"2016","journal-title":"Trends Anal. Chem."},{"issue":"1","key":"10.1016\/j.clinbiochem.2018.04.001_bb0115","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12885-015-1275-0","article-title":"Feasibility of self-sampled dried blood spot and saliva samples sent by mail in a population-based study","volume":"15","author":"Sakhi","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clinbiochem.2018.04.001_bb0120","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.trac.2017.12.004","article-title":"Dried matrix spots and clinical elemental analysis. Current status, difficulties, and opportunities","volume":"99","author":"Resano","year":"2017","journal-title":"TrAC Trends Anal. Chem."},{"issue":"4","key":"10.1016\/j.clinbiochem.2018.04.001_bb0125","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/sj.bjp.0705651","article-title":"Circadian rhythm of dihydrouracil\/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels","volume":"141","author":"Jiang","year":"2004","journal-title":"Br. J. Pharmacol."},{"issue":"13\u201314","key":"10.1016\/j.clinbiochem.2018.04.001_bb0130","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.clinbiochem.2015.04.019","article-title":"Improved determination of uracil and dihydrouracil in plasma after a loading oral dose of uracil using high-performance liquid chromatography with photodiode array detection and porous graphitic carbon stationary phase","volume":"48","author":"Hahn","year":"2015","journal-title":"Clin. Biochem."},{"issue":"4","key":"10.1016\/j.clinbiochem.2018.04.001_bb0135","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1177\/147323001003800413","article-title":"The value of Dihydrouracil\/uracil plasma ratios in predicting 5-fluorouracil-related toxicity in colorectal Cancer patients","volume":"38","author":"Kristensen","year":"2010","journal-title":"J. Int. Med. Res."},{"issue":"1","key":"10.1016\/j.clinbiochem.2018.04.001_bb0140","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/bcp.12790","article-title":"Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer","volume":"81","author":"Launay","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2018.04.001_bb0145","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2006.09.006","article-title":"5-fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency","volume":"249","author":"Boisdron-Celle","year":"2007","journal-title":"Cancer Lett."},{"issue":"11","key":"10.1016\/j.clinbiochem.2018.04.001_bb0150","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/bjc.2017.94","article-title":"Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity","volume":"116","author":"Meulendijks","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.clinbiochem.2018.04.001_bb0155","first-page":"3853","article-title":"Determination of 5-fluorouracil in plasma using high-performance liquid chromatography with porous graphitic carbon stationary phase and diode array detection","volume":"35","author":"Tang","year":"2016","journal-title":"Lat. Am. J. Pharm."},{"issue":"4","key":"10.1016\/j.clinbiochem.2018.04.001_bb0160","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1634\/theoncologist.7-4-288","article-title":"Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review","volume":"7","author":"Malet-Martino","year":"2002","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.clinbiochem.2018.04.001_bb0165","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s00280-016-3184-6","article-title":"Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial","volume":"78","author":"Denda","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"2","key":"10.1016\/j.clinbiochem.2018.04.001_bb0170","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00280-012-2018-4","article-title":"Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study","volume":"71","author":"Mueller","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"13","key":"10.1016\/j.clinbiochem.2018.04.001_bb0175","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.2217\/pgs.14.126","article-title":"Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio","volume":"15","author":"Sistonen","year":"2014","journal-title":"Pharmacogenomics"}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912018301462?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912018301462?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:52:34Z","timestamp":1757865154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912018301462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":35,"alternative-id":["S0009912018301462"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2018.04.001","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicity","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2018.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}